1 / 31

Proteomics and “Orphan” Receptors

Proteomics and “Orphan” Receptors. Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703) 308-6564 yvonne.eyler@uspto.gov. What is Proteomics?. Proteomics refers to the systematic analysis of protein profiles of entire cells, tissues, organisms, or species.

jaxon
Download Presentation

Proteomics and “Orphan” Receptors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703) 308-6564 yvonne.eyler@uspto.gov

  2. What is Proteomics? • Proteomics refers to the systematic analysis of protein profiles of entire cells, tissues, organisms, or species. • It represents the protein counterpart to the analysis of gene function.

  3. Why is Proteomics Important? • Identification of proteins in normal and disease conditions • Investigating epidemiology and taxonomy of pathogens • Analysis of drug resistance • Identification of pathogenic mechanisms • Reveals gene regulation events involved in disease progression • Pin-point targets for drug discovery • Contributes to understanding of gene function

  4. Proteomic Methodologies • Analysis of protein expression patterns • Analysis of protein Sequence Information • Analysis of protein structure/function relationships

  5. What is an “orphan” receptor? • An “orphan” receptor is a receptor with no known biological function. • An “orphan” receptor is a receptor with no known ligand.

  6. Patentability • Patent Statutes • 35 USC 101, Utility • 35 USC 102, Anticipation • 35 USC 103, Obviousness • 35 USC 112, 1st Paragraph, enablement • 35 USC 112, 1st Paragraph, written description • 35 USC 112, 2nd Paragraph

  7. Expression Patterns2D Gel

  8. Specification • The specification discloses 2D gels of proteins present in prostate cancer cell lysates and normal cell lysates. • A polypeptide located in a spot unique to prostate cancer cells was isolated and sequenced (SEQ ID NO: 1) • SEQ ID NO: 1 has 45% homology to WOW, a G protein coupled receptor which is up-regulated in prostate cancer which binds ligand B. • Blocking of WOW/ligand B binding inhibits prostate cancer growth.

  9. An Example Claim • An isolated polypeptide comprising SEQ ID NO: 1.

  10. Utility Consideration • The asserted utility for SEQ ID NO: 1 is for use in screening assays to identify agents which bind to it. The agents are then to be used to inhibit prostate cancer growth. • The asserted utility is based on the 45% homology to WOW receptor.

  11. Sequence Homology is Usually Insufficient to Establish Utility • Receptor function cannot be reliably predicted from DNA or protein sequence homology • Evolutionarily-related protein families may have both overlapping and distinct features

  12. Example #1 of Homology being Insufficient Criteria for Utility • Transforming Growth Factor (TGF-beta) Family • OP-1 induces metanephrogenesis whereas closest related TGF-beta family members—BMP-2 and TGF-beta1—have no effect on metanephrogenesis under identical conditions

  13. Example #2 of Homology Being Insufficient Criteria for Utility • Platelet-derived Growth Factor (PDGF) Family • VEGF, a member of the PDGF family, is mitogenic for vascular endothelial cells but not for vascular smooth muscle cells • PDGF is mitogenic for vascular smooth muscle cells but not for vascular endothelial cells

  14. Example #3 of Homology Being Insufficient Criteria for Utility • Vertebrate growth hormone of 198 amino acids becomes an antagonist (inhibitor of growth) when a single amino acid is changed. Even 99% homology does not allow predictability in this instance.

  15. Utility Considerations for the Claim Example • SEQ ID NO: 1 is an “orphan” receptor with no known ligand and no known function. • The asserted utility is based solely on sequence homology to a G protein coupled receptor. • G protein coupled receptors are a large and diverse family of receptors with diverse functions and properties, having no well established utility based on family membership.

  16. Conclusion • The claimed polypeptide would not be found to have a specific, substantial, and credible asserted or well established utility.

  17. Specification # 2 • The specification still discloses 2D gels of prostate cancer and normal cell lysates. • The polypeptide of SEQ ID NO: 1 is an “orphan” receptor. • Antibodies were generated to SEQ ID NO: 1 • The antibodies were used in a series of binding assays to demonstrate a clear correlation between presence of high levels of SEQ ID NO: 1 and prostate cancer.

  18. An Example Claim • An isolated polypeptide comprising SEQ ID NO: 1.

  19. Utility Consideration • The asserted utility for SEQ ID NO: 1 is for use to diagnose prostate cancer.

  20. Utility Conclusion • The asserted utility is specific to the polypeptide of SEQ ID NO: 1. • The asserted utility is substantial. • The asserted utility is credible.

  21. Written DescriptionConsiderations

  22. An Example Claim Set • An isolated polypeptide comprising at least 10 contiguous amino acids of SEQ ID NO: 1. • An isolated polypeptide having at least 45% identity to the polypeptide of SEQ ID NO: 1.

  23. Satisfying Written Description • Weigh factual considerations in view of level of skill and knowledge in the art • Complete or partial structure • Physical and/or chemical properties • Functional characteristics • Correlation between structure and function • Method of making • Combinations of the above

  24. Physical properties of a single polypeptide are disclosed, ie molecular weight and pI by 2D gel electrophoresis and its sequence. The physical properties of polypeptides comprising 10 amino acids or of polypeptides having 45% identity to SEQ ID NO: 1 are not disclosed or known in the art. No biological function of the polypeptide of SEQ ID NO: 1 is disclosed. The isolated polypeptide is an “orphan” receptor. No structural to functional correlation is disclosed between core structural features needed to retain function in the two claimed genus of polypeptides. Written Description Analysis

  25. Conclusion • Applicant was not in possession of the claimed genus of isolated polypeptides.

  26. EnablementConsiderations

  27. Satisfying the Enablement Requirement • Factors to be considered, In re Wands, 858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988) • Quantity of experimentation necessary • Amount of direction or guidance presented • Presence or absence of working examples • Nature of the invention • State of the prior art • Relative skill of those in the art • Predictability or unpredictability of the art • Breadth of the claims

  28. No guidance regarding the critical structural features of the polypeptide of SEQ ID NO: 1. Which 10 amino acids are essential to functional and physical properties? Where over the length of the polypeptide may changes be made up to 45% identity and still retain functional and physical properties? There is no function for the isolated polypeptide. It is an “orphan” receptor. It is not predictable that the scope of the claimed polypeptides could be used to diagnose prostate cancer. Enablement Analysis

  29. Conclusion • The specification was not enabling for the scope the claimed isolated polypeptides.

  30. Solution Claim: • An isolated polypeptide comprising SEQ ID NO: 1.

  31. Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703) 308-6564 yvonne.eyler@uspto.gov

More Related